The Course of Levodopa-treated Parkinson”s disease
Objective: The advantages and disadvantages of Lewodopa in treating Parkinson”s disease (PD) have been discussed widely in recent years. To investigate the effect of Levodopa on thc course of PD, thc clinical data of 43 cases of PD wcrc revicwcd. Methods: We Selected 43 cases of clinical diagnosed Parkinson”s disease patients who were treated with Levodopa before and the medical history were recorded detailedly. The clinical features of these cases such as the onset age; the disease course; the H-Y scale at the end of the follow-up were analysed and compared with literatures. Results: The average age of the 43 cases is 65.9 years old 28 cases are male and 15 cases are female. The average onset age is 58.5 years. The average period of the disease course is 7.67 years for the total 43cases. The score of H-Y scale at the end of the follow-up is 2.52. For the 43 cases, The average course of the 6 cases scaled as 1-1.5 is 2.75 years. 17 cases scaled as 2 is 6.29 years. 13 cases scaled as 2.5-3 is 7.54 years.4 cases scaled as 4 is 12.5years and 3 cases scaled as 5 is 10.7 years. 43 cases are divided into 3 groups according to the length of disease course.20 (46.5%) of the 43 cases are less than 5 years, in which 17 cases(g5%) are classified as mild(H-Y scale 1 and 2) ,2 cases are moderale (H-Y scale 2.5-3),1 case is severe (H-Y scale 4-5).The courses of 13(30.2%) of the 43 cases are 5-10 years, 5(38.5%) are mild,7(53.8%)are moderate and 1(7.7%) is severe. And 10 (23.3%) of 43 are more than 10 years, in which 1 (10%)is mild, 4(40%) are moderate ,5(50%) are severe. For the 23 cases over 5 years, 11 cases were treated with Levodopa before 5 years of the period of disease course, which reached 3.05 of the average H-Y scale at the end of the fo11ow-up. The other 12 cases were treated with Levodopa after 5 years of the disease course, the average H-Y scale is 2.83 at the end of the follow-up. Conclusion: Compared with literatures, our data suggests that Levodopa does not affect the course of Parkinson′s disease. The progression of the Parkinson”s disease measured by the H-Y scale is related to the length of the disease period. But most patient less than 10 years are stay below H-Y 3 scale, Levodopa may improve the life quality of PD patients. It is likely that the time at which Levodopa treatment began is not related to the severity of disease progression
advantages and disadvantages、clinical features、life quality、average age
8
TG2;TG1
2005-07-07（万方平台首次上网日期，不代表论文的发表时间）
共1页
26
